COVID-19 vaccinations are now available to everyone 12 years and older. Roll up your sleeve and join the fight.

Clinical Trials

Showing 1-10 of 47 Results

Pediatric Oncology Trials – AREN1721 – Phase II

AREN1721 – Phase II A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Pediatric Oncology Trials – AALL1821 – Phase II

AALL1821 – Phase II A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse

Pediatric Oncology Trials – AAML1831 – Phase III

AAML1831 – Phase III A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

Pediatric Oncology Trials – ANBL1531: Phase III

ANBL1531:  Phase III Aim: Testing the addition of I-MIBG or Crizotinib to intensive therapy in children and adults with high-risk neuroblastoma (NBL).

Pediatric Oncology Trials – ANBL00B1

ANBL00B1 Aim: To analyze biomarkers in tumor tissue samples from patients with newly diagnosed Neuroblastoma or Ganglioneuroblastoma

Pediatric Oncology Trials – AALL1631: Phase III

AALL1631: Phase III Aim: A study of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones.

Pediatric Oncology Trials – AALL1731: Phase III

AALL1731: Phase III Aim: A study to compare the addition of Blinatumomab in combination with chemotherapy in patients diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B‑ALL and the treatment of patients with localized B-cell Lymphoblastic Lymphoma (B-LLy).

Pediatric Oncology Trials – AALL1732: Phase III

AALL1732: Phase III Aim: A study to test if the addition of Inotuzumab Ozogamicin (InO) to standard chemotherapy treatment in patients diagnosed with National Cancer Institute (NCI) High-Risk (HR) B-cell Acute Lymphoblastic Leukemia (B-ALL) or NCI Standard-Risk (SR) BALL with high risk features improves outcomes.

Pediatric Oncology Trials – APEC14B1: The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study

APEC14B1: The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study Aim: A childhood cancer registry of infants, children, adolescents, and young adults with cancer called Project:EveryChild, which supports current and future therapeutic clinical trials and the discovery efforts that will lead to more effective therapies, prevention, earlier…

Quality of Life Studies – Cancer Genetic Syndromes Study

Cancer Genetic Syndromes Study A prospective survey of the patients’ understanding on genetic tests for cancer genetic syndromes.

Showing 1-10 of 47 Results